calling biotech, page-4

coppashaft,

These products are not targeted for revenue primarily. Though the following quote from CEO's recent interview will not answer your question directly, however, that may help understanding the reason behind launching of these products:

Geoff Cumming: What we’ve found in the work we’ve done to date is that we’re very much dependent upon the decisions of third parties, for our success. And so we’re under their control in a sense. What we wanted to do was to a limited extent, gain control over our own destiny. So as a result, we’ve now got a couple of products on the market, two and they are Streptavidin coated beads and Streptavidin coated plates. Through the course of this year, we’d expect to launch perhaps four to six new products.

Now the revenues that we get from those of course will help to sustain us as an organisation. But from my perspective more importantly, the fact that those products are on the market and selling commercially, lowers any perceived risk that might be in the minds of some of the other significant parties that we’re dealing with.
……………………………………………………………………………….
Our main revenue stream we expect to be, royalties from inclusion of our product into major commercially successful products.